Vipera palaestinae bite and serum sickness during pregnancy.

J Emerg Med

Israel Poison Information Center, Rambam Health Care Campus, The Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Published: June 2010

Background: Vipera palaestinae is the most common venomous snake in Israel. We report a case of V. palaestinae bite and antivenom-induced serum sickness during pregnancy and discuss the unique considerations relevant to the treatment of a pregnant woman envenomated by a snake.

Case Report: A 46-year-old woman, G6P5, 14 weeks gestation, was admitted after a V. palaestinae bite on her right toe. On admission to the Emergency Department, physical examination included the following vital signs and findings: pulse 76 beats/min, blood pressure 90/60 mm Hg, nausea, vomiting, foot and distal leg swelling, and normal fetal monitoring. She was treated with intravenous fluids, analgesics, and V. palaestinae antivenom. Eight days later she developed serum sickness, was treated with prednisone, and fully recovered. A healthy baby was born at term, with normal examination at 2 months post-delivery.

Conclusion: To our knowledge, this is the first reported case of V. palaestinae bite complicated by antivenom-induced serum sickness during pregnancy. No adverse pregnancy outcome due to the antivenom treatment or serum sickness was observed. Careful hemodynamic, hematologic, and obstetric monitoring (including ultrasound) of pregnant snakebite victims is warranted. Antivenom administration should be considered according to published indications to prevent maternal complications and fetal compromise. Patients treated with antivenom should be followed for possible development of serum sickness.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jemermed.2009.02.007DOI Listing

Publication Analysis

Top Keywords

serum sickness
24
palaestinae bite
16
sickness pregnancy
12
vipera palaestinae
8
case palaestinae
8
antivenom-induced serum
8
serum
6
sickness
6
palaestinae
5
bite
4

Similar Publications

High-altitude pulmonary edema (HAPE) is a life-threatening altitude sickness afflicting certain individuals after rapid ascent to high altitude above 2500 m. In the setting of HAPE, an early diagnosis is critical and currently based on clinical evaluation. The aim of this study was to utilize the metabolomics to identify the altered metabolic patterns and potential biomarkers for HAPE.

View Article and Find Full Text PDF

Previous studies have reported high diversity between and within populations of Toxoplasma gondii in South America. In the present study, isolates of T. gondii from chickens were obtained from the Amazon region.

View Article and Find Full Text PDF

Background: Interleukin-23 inhibition is effective in treating ulcerative colitis. Guselkumab is a dual-acting, human IgG1, interleukin-23p19 subunit inhibitor that potently neutralises interleukin-23 and can bind to CD64. We aimed to evaluate the efficacy and safety of guselkumab as induction and maintenance therapy in patients with ulcerative colitis.

View Article and Find Full Text PDF

Nobiletin-rich kososan, a Kampo formula, prevents the onset of apathy-like behavior and neuroinflammation in sickness behavior mouse model induced by increasing doses of lipopolysaccharide.

Neuroscience

December 2024

Laboratory of Kampo Clinical Research, Oriental Medicine Research Center, School of Pharmacy, Kitasato University, Tokyo, Japan; Department of Pharmacognosy, School of Pharmacy, Kitasato University, Tokyo, Japan.

Infectious diseases are often concomitant with symptoms of lassitude and emotional disturbances, including depression, the so-called sickness behavior. Kososan, a Kampo (traditional Japanese herbal) formula, has been clinically used for depressive mood, with demonstrated efficacy in stress-induced depressive-like behavior mouse models. Additionally, our previous study has shown that nobiletin-rich kososan (NKS) prevents aging-related depressive-like behaviors and neuroinflammation in mice.

View Article and Find Full Text PDF

Chronic high-altitude hypoxia (CHH) induces irreversible abnormalities in various organisms. Emerging evidence indicates that CHH markedly suppresses bone mass and bone strength. Targeting senescent cells and the consequent senescence-associated secretory phenotype (SASP) with senolytics is a recently developed novel therapy for multiple age-related diseases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!